Henry S - Search Results

1

The Oligonucleotide Safety Working Group (OSWG).

Schubert D, Levin AA, Kornbrust D, Berman CL, Cavagnaro J, Henry S, Seguin R, Ferrari N, Shrewsbury SB. Schubert D, et al. Among authors: henry s. Nucleic Acid Ther. 2012 Aug;22(4):211-2. doi: 10.1089/nat.2012.0383. Nucleic Acid Ther. 2012. PMID: 22913593 No abstract available.

2

An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI. Bennett CF, et al. Among authors: henry s. J Pharmacol Exp Ther. 1997 Feb;280(2):988-1000. J Pharmacol Exp Ther. 1997. PMID: 9023316

3

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ. Henry SP, et al. J Pharmacol Exp Ther. 1997 May;281(2):810-6. J Pharmacol Exp Ther. 1997. PMID: 9152389

4

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

Henry SP, Bolte H, Auletta C, Kornbrust DJ. Henry SP, et al. Toxicology. 1997 Jun 27;120(2):145-55. doi: 10.1016/s0300-483x(97)03661-5. Toxicology. 1997. PMID: 9184201

5

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Geary RS, et al. Among authors: henry sp. Anticancer Drug Des. 1997 Jul;12(5):383-93. Anticancer Drug Des. 1997. PMID: 9236854 Review. No abstract available.

6

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

Henry SP, Monteith D, Levin AA. Henry SP, et al. Anticancer Drug Des. 1997 Jul;12(5):395-408. Anticancer Drug Des. 1997. PMID: 9236855 Review. No abstract available.

7

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

Henry SP, Monteith D, Bennett F, Levin AA. Henry SP, et al. Anticancer Drug Des. 1997 Jul;12(5):409-20. Anticancer Drug Des. 1997. PMID: 9236856 Review. No abstract available.

8

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

Leeds JM, Henry SP, Truong L, Zutshi A, Levin AA, Kornbrust D. Leeds JM, et al. Among authors: henry sp. Drug Metab Dispos. 1997 Aug;25(8):921-6. Drug Metab Dispos. 1997. PMID: 9280399

9

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. doi: 10.1089/oli.1.1997.7.473. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361906

10

Inhibition of coagulation by a phosphorothioate oligonucleotide.

Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10. doi: 10.1089/oli.1.1997.7.503. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,556 results

Search Page

Filters